MarketPulse

Breakthrough Therapy

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Oculis Holding Ag

Oculis Gains European Fast-Track Status for Optic Neuritis Drug Privosegtor

Oculis secures EMA PRIME fast-track designation for Privosegtor, a potential first-in-class neuroprotective optic neuritis therapy, following FDA Breakthrough status in January 2026.
OCSOCSAWclinical trialsrare disease
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Scores EMA PRIME Designation for Optic Neuritis Drug Privosegtor

Oculis' neuroprotective candidate Privosegtor receives EMA PRIME designation for optic neuritis, following FDA Breakthrough designation and positive Phase 2 data.
OCSOCSAWrare diseaseorphan drug